Sython is a leading international pharmaceutical company. BC Partners acquired its majority stake in Synthon from the company’s founders in 2019 through a bilateral transaction. Leveraging its significant pharmaceutical and generic drugs sector expertise – gained through prior investments such as Pharmathen - BC Partners, together with the management, was able to drive significant organic growth and geographic expansion with a focus on commercial excellence, R&D, technology differentiation, and operational excellence. Since the initial investment five years ago, Synthon has more than doubled EBITDA and cemented its leading position in the sector.
Joost den Engelsman leads the NautaDutilh team, that further consists of Olaf Baks, Yassir Zuidi, Nienke van der Meer, Sanne Mesu, Belen Gobits, Jules van de Winckel, Florine Kuiperi, Godelieve Verburg, Lisse Offringa, Daniel Kuiper, Annette van Beers, Laura Zijp, Pieter de Jong, Ramon Pop, Jeroen Boelens, and Jesper Vrielink.
About Synthon
Synthon is a global leader in developing, manufacturing, and out-licensing complex generic medicines. The company was founded by Dr. Jacques Lemmens in 1991. Headquartered in Nijmegen, The Netherlands, Sython has offices in eight other countries, and four R&D labs and four manufacturing sites in Czech Republic, Spain, Argentina and Chile, employing about 1.600 people. Synthon serves over 200 customers in approximately 100 countries.
Press releases: